Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biomarin Pharmaceutical Inc. (BMRN)
:BMRN
RESEARCH TOOLSreports
BioMarin Pharmaceutical (BMRN) Ownership Overview
0.95% Insiders
36.73% Mutual Funds
0.42% Other Institutional Investors
22.51% ETFs
39.39% Public Companies and Individual Investors
The ownership structure of BioMarin Pharmaceutical (BMRN) stock is a mix of institutional, retail, and individual investors. Approximately 59.66% of the company’s stock is owned by Institutional Investors, 0.95% is owned by Insiders, and 39.39% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Nov 14, 2024 | Charles Greg Guyer Evp, Cto | xxxxxxxxxxxxx | $350301 |
| Mar 07, 2024 | Henry Fuchs President, Worldwide R&d | xxxxxxxxxxxxx | $3010346 |
| Mar 07, 2024 | Jean Jacques Bienaime Director | xxxxxxxxxxxxx | $172220 |
| Feb 29, 2024 | Jean Jacques Bienaime Director | xxxxxxxxxxxxx | $90350 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2024 | xxxxxxxxxxxxx | $1380 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $917985 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 18,402,668 | Institution | 9.66% | 1,193,413,020 | |
| 18,189,171 | Institution | 9.54% | 1,179,567,739 | |
| 16,888,744 | Institution | 8.86% | 1,095,235,048 | |
| 14,746,235 | Institution | 7.74% | 956,293,340 | |
| 13,130,387 | Institution | 6.89% | 851,505,597 | |
| 10,543,625 | Institution | 5.53% | 683,754,081 | |
| 9,753,293 | Institution | 5.12% | 632,501,051 | |
| 7,270,808 | Institution | 3.82% | 471,511,899 | |
| 6,405,939 | Institution | 3.36% | 415,425,144 | |
| 5,672,912 | Institution | 2.98% | 367,888,343 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 16,888,744 | Institution | 8.86% | 1,095,235,048 | |
| 10,543,625 | Institution | 5.53% | 683,754,081 | |
| 7,270,808 | Institution | 3.82% | 471,511,899 | |
| 6,405,939 | Institution | 3.36% | 415,425,144 | |
| 5,672,912 | Institution | 2.98% | 367,888,343 | |
| 4,494,821 | Institution | 2.36% | 291,489,142 | |
| 3,355,166 | Institution | 1.76% | 217,582,515 | |
| 2,022,822 | Institution | 1.06% | 131,180,007 | |
| 1,895,769 | Institution | 0.99% | 122,940,620 | |
| 808,714 | Institution | 0.42% | 52,445,103 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 6,165,737 | Institution | 3.24% | 397,196,778 | |
| 5,998,183 | Institution | 3.15% | 394,260,569 | |
| 2,891,111 | Institution | 1.52% | 190,032,726 | |
| 2,424,636 | Institution | 1.27% | 159,371,324 | |
| 2,184,006 | Institution | 1.15% | 140,693,667 | |
| 2,047,988 | Institution | 1.07% | 134,614,251 | |
| 1,552,611 | Institution | 0.81% | 100,019,201 | |
| 1,373,769 | Institution | 0.72% | 90,297,836 | |
| 1,325,626 | Institution | 0.70% | 87,133,397 | |
| 1,177,512 | Institution | 0.62% | 76,361,653 |
FAQ
Who Owns Biomarin Pharmaceutical Inc. (BMRN)?
According to the latest TipRanks data, approximately 0.42% of the company's stock is held by institutional investors, 0.95% is held by insiders, and 39.39% is held by retail investors.
What percentage of Biomarin Pharmaceutical Inc. (BMRN) stock is held by institutional investors?
According to the latest TipRanks data, approximately 0.42% of Biomarin Pharmaceutical Inc. (BMRN) stock is held by institutional investors.
What percentage of Biomarin Pharmaceutical Inc. (BMRN) stock is held by retail investors?
According to the latest TipRanks data, approximately 39.39% of Biomarin Pharmaceutical Inc. (BMRN) stock is held by retail investors.
Who owns the most shares of Biomarin Pharmaceutical Inc. (BMRN)?
Vanguard owns the most shares of Biomarin Pharmaceutical Inc. (BMRN).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.